BioAge Labs, Inc. (NASDAQ:BIOA) Short Interest Up 82.2% in January

BioAge Labs, Inc. (NASDAQ:BIOA) was the recipient of a large increase in short interest in the month of January. As of January 15th, there was short interest totaling 1,085,882 shares, an increase of 82.2% from the December 31st total of 596,127 shares. Approximately 3.8% of the company’s stock are sold short. Based on an average trading volume of 1,128,484 shares, the days-to-cover ratio is presently 1.0 days. Based on an average trading volume of 1,128,484 shares, the days-to-cover ratio is presently 1.0 days. Approximately 3.8% of the company’s stock are sold short.

Insider Buying and Selling at BioAge Labs

In other BioAge Labs news, CEO Kristen Fortney sold 233,107 shares of the stock in a transaction on Tuesday, January 13th. The shares were sold at an average price of $18.12, for a total transaction of $4,223,898.84. Following the transaction, the chief executive officer directly owned 976,949 shares in the company, valued at $17,702,315.88. This represents a 19.26% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Dov A. Md Goldstein sold 27,000 shares of BioAge Labs stock in a transaction on Tuesday, January 13th. The stock was sold at an average price of $19.70, for a total transaction of $531,900.00. Following the completion of the transaction, the chief financial officer directly owned 22,408 shares of the company’s stock, valued at approximately $441,437.60. This represents a 54.65% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 347,004 shares of company stock valued at $5,673,859 over the last 90 days. 20.82% of the stock is owned by corporate insiders.

Institutional Trading of BioAge Labs

Institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. raised its holdings in shares of BioAge Labs by 6.0% in the third quarter. Vanguard Group Inc. now owns 1,651,247 shares of the company’s stock valued at $9,709,000 after purchasing an additional 93,694 shares during the last quarter. Geode Capital Management LLC lifted its position in BioAge Labs by 60.8% during the 2nd quarter. Geode Capital Management LLC now owns 453,455 shares of the company’s stock worth $1,873,000 after buying an additional 171,426 shares in the last quarter. Millennium Management LLC grew its holdings in shares of BioAge Labs by 749.8% in the 3rd quarter. Millennium Management LLC now owns 306,552 shares of the company’s stock valued at $1,803,000 after acquiring an additional 270,479 shares in the last quarter. Marshall Wace LLP increased its position in shares of BioAge Labs by 324.7% in the second quarter. Marshall Wace LLP now owns 226,789 shares of the company’s stock valued at $937,000 after acquiring an additional 173,388 shares during the last quarter. Finally, Stonepine Capital Management LLC raised its holdings in BioAge Labs by 202.2% during the second quarter. Stonepine Capital Management LLC now owns 151,085 shares of the company’s stock worth $624,000 after acquiring an additional 101,085 shares in the last quarter.

Wall Street Analyst Weigh In

Several analysts have issued reports on BIOA shares. Citigroup boosted their price objective on BioAge Labs from $10.00 to $15.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioAge Labs in a research report on Tuesday. Piper Sandler started coverage on BioAge Labs in a report on Tuesday. They issued an “overweight” rating on the stock. Finally, Wall Street Zen cut shares of BioAge Labs from a “hold” rating to a “sell” rating in a research note on Monday, January 26th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, BioAge Labs has an average rating of “Hold” and an average target price of $15.00.

BioAge Labs Trading Down 0.6%

BIOA traded down $0.11 during midday trading on Friday, reaching $18.99. The company’s stock had a trading volume of 580,476 shares, compared to its average volume of 1,022,327. The stock has a market cap of $680.79 million, a P/E ratio of -12.49 and a beta of 1.38. BioAge Labs has a twelve month low of $2.88 and a twelve month high of $24.00. The company has a fifty day simple moving average of $14.49 and a 200 day simple moving average of $8.68.

BioAge Labs (NASDAQ:BIOA) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.56) EPS for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.11. The firm had revenue of $2.05 million during the quarter.

BioAge Labs Company Profile

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.